TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT07290244: Evaluating ER-100 for Safety in People With Glaucoma or Non-Arteritic Anterior Ischemic Optic Neuropathy (Optic Nerve Conditions)

Sponsor: Life Biosciences Inc. · Phase: PHASE1 · Area: CNS_NEUROLOGY · Target Enrollment: 20 pts

Competing Trials Overlap

5 Active Trials

Excess Burn Exposure

$712,368

Rescue Site Savings

+$474,912

Unlock Full NCT07290244 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07290244 Rescue Dossier →